Author Index

A

Aamo T, 248
Aarnoudse A-JLHJ, 9
Aboujaoude E, 51
Abreu-Gonzalez P, 97
Adams CE, 141
Adams WH, 484
Adler LA, 44, 239
Adli M, 327
Agyapong VIO, 565
Ahmed S, 39
Ahn YM, 117
Aia PG, 185
Ak M, 620
Akhondzadeh S, 182
Alam A, 102
Alexander MM, 409
Alpert JE, 372
Alphs L, 542
Álvarez-Dobanõ JM, 310
Amiaz R, 216
Amsterdam JD, 378, 478
Andreassen OA, 109
Andretta M, 33
Angelini MC, 190
Anghelescu IG, 170
Ansermot N, 319
Anton RF, 334
Arends J, 16
Arias A, 350
Armeli S, 350
Arrojo-Romero M, 310
Artiges E, 86
Asada T, 499
Asnis GM, 222
Ataoglu A, 368
Azulay J-P, 548

B

Bagoien G, 248
Bagnardi V, 9
Bai Y-M, 529
Baker B, 412
Baker RA, 362
Ball SG, 96
Bangaru R, 565
Bangs ME, 453
Barbui C, 33
Baros AM, 334
Barron J, 26
Barry JJ, 51
Barth FX, 492
Bastani B, 222
Bau CHD, 614
Bauer AD, 291
Bauer M, 327
Baumann P, 319
Becker RE, 56
Beglinger LJ, 484
Bellodi L, 343
Belmonte-de-Abreu P, 614
Bergstrom RF, 278
Berlin I, 86
Berman RM, 92, 362
Berti A, 33
Beversdorf DQ, 101
Birkeland KI, 109
Birkenaes AB, 109
Birkenhäger TK, 513
Bittner DM, 511
Blin O, 548
Bode-Böger SM, 402
Bodkin JA, 96
Bokde ALW, 147
Boks M, 513
Bolton JM, 497
Bopp K, 201
Borba CP, 165
Born C, 147
Bosch J, 267
Bossie CA, 542
Bottlaender M, 86
Bourdel MC, 304
Bourgeois S, 86
Boxill R, 165
Bozkurt H, 508
Bozzini L, 33
Bragulat V, 86
Brandner B, 124
Brands B, 231, 77
Brauchli YB, 134
Brina D, 576
Bromley LM, 124
Brown B, 83
Brown ES, 284
Brown TE, 44
Bruggeman R, 399
Bruijn JA, 513
Brunetto M, 504
Burczynski ME, 39
Burd L, 1
Burger H, 288
Burger R, 392

C

Canan F, 368
Cancelli I, 313
Canuso CM, 542
Caprioli A, 576
Carballal-Calvo F, 310
Cargile C, 488
Carroll BJ, 90
Carvalho DLB, 306
Casamassima F, 504
Casey DE, 267
Cassano GB, 504
Castberg I, 415
Cather C, 165
Cavedini P, 343
Centorrino F, 595
Chambers CD, 555
Chan G, 350
Chang J, 595
Chang Y-C, 391
Chaudhry S, 453
Chavez B, 307
Chen H, 95
Chen J-Y, 529
Chen L, 278, 311
Chen S-Y, 529
Chen T-T, 529
Chen VC-H, 95
Cheng W-C, 616
Chengappa KNR, 193
Chiesa A, 259
Chiu C-C, 506
Cho H-K, 272
Choi JS, 117
Chong S-A, 5
Chopra MP, 488
Chou J-y, 95
Chriki L, 291
Christensen T, 1
Chung I-W, 117
Cipriani A, 33
Citrome L, 278
Clarke M, 606
Coccurello R, 576
Codesido-Barcala R, 310
Cohen D, 16, 21
Conti R, 576
Contini V, 614
Cook IA, 372
Cook-Wiens G, 492
Copeland PM, 165
Coryell W, 174
Coskun M, 508, 607
Covault J, 350
Cregg R, 124
Crettol S, 319
Crippa JAS, 306
Crystal S, 307
Cuffel B, 26
Curran HV, 124
Curtin F, 134
Czock D, 622

D

D'Arienzo F, 33
Dahl M-L, 65
Dahmen N, 191
Danese A, 504
Danker-Hopfe H, 170
Das RK, 124
Davis JM, 296
De Koning FHP, 405
de la Asuncion Elvira J, 439
de Leon J, 201, 310, 509
De León OA, 503
De Rosa M, 33
De Vitis G, 33
de Wit NJ, 288
Deboeck P, 609
Deckert J, 392
Degenhardt EK, 520
Delaveau P, 548
Denninger JW, 73
Derijks HJ, 405
Desai S, 284
Diaz B, 358
Diaz FJ, 201
Diehl A, 99
Dizio S, 190
Dolianitis K, 183
Dollé F, 86,
Dording C, 73
Duff K, 484
Dunn E, 77
Dunn RT, 291
Dunsmore S, 497

E

Eap CB, 319
Egberts ACG, 16, 21, 405
Egberts TCG, 69
El-Gaaly S, 497
Elkader AK, 77, 231
Epelbaum J, 304
Esper CD, 185
Evins AE, 165

F

Factor SA, 185
Fakra E, 548
Fan X, 165
Fava M, 73, 222, 362
Feldman Z, 488
Fernández-Pérez R, 310
Ferrari MCF, 306
Fiedorowicz JG, 484
Filkowski MM, 291
Fleming MW, 509
Folsom DP, 210
Fornaro G, 391
Franke B, 16
Freeman EW, 403
Freudenreich O, 165
Friis S, 109
Frye C, 403
Fumero I, 358

G

Gagne JJ, 590
Gagnon DD, 496
Gamel N, 51
Garcia-Hernandez A, 97
Gardarsdottir H, 69
Garza VM, 503
Gau SSF, 529
Gentry WB, 488
George TP, 193, 601
Gerhard T, 307
Ghaeli P, 182
Ghaemi SN, 291
Ghio L, 391
Ghirardi O, 576
Gigli GL, 313
Gilmer WS, 291,
Gispen-de Wied C, 16,
Glick ID, 267, 542
Glorioso DK, 210
Goff DC, 165
Goodman M, 396
Gracia CR, 403
Graff-Guerrero A, 571
Grassi M, 343
Grégoire M-C, 86
Gregoor JG, 21
Greig NH, 56

Grevet EH, 614
Grobbee DE, 288
Grouselle D, 304
Grunze HCR, 409
Guico-Pabia CJ, 383
Gulsun M, 620
Gumus HO, 620
Gunes A, 65
Gupta M, 501

H

Haiman G, 444
Hajak G, 618
Hameister J, 622
Hampel H, 147
Han C, 272
Hanlon RE, 291
Harada T, 301
Harenberg S, 319
Harmatz JS, 105
Harvey PD, 291, 396
Hashemian F, 182
Hashimoto K, 411
Hasnain M, 102
Hatch JP, 296
Heerdink ER, 21, 69, 405
Heima M, 426
Helldén A, 302
Hellings JA, 492
Henderson DC, 165
Hendset M, 537
Henry M, 97
Henry R, 210
Hermann M, 537
Hernández-Díaz S, 555
Hetem LAB, 306
Heuser I, 170
Hiemke C, 191, 392
Hilliker S, 73
Hitsman B, 601
Hofman A, 9
Hojjat SK, 314
Holdnack J, 44
Holick CN, 453
Homberger C, 73
Hori T, 499
Hosaka K, 426
Höschl C, 409
Hosseini SH, 182
Hough D, 496
Howes OD, 195
Hsiao S-H, 506
Hsieh MH, 616
Hu Q, 296
Hundal H, 195
Hunter AM, 372
Hwang C, 609
Hwang SS-H, 117
Hwang T-J, 398, 616

I

Ishigooka J, 301
Ishikawa K, 499, 619
Isler JA, 39

J

Jabs B, 392
Jackson DL, 426
Jacobson JG, 278, 520
Jamal HH, 358
Jana AK, 604
Janknegt R, 405
Janowsky DS, 296
Janzing JGE, 513
Javanbakht A, 314
Jazayeri M, 182
Jefferson JW, 622
Jeste DV, 210
Jiang Q, 39
Jick SS, 134
Jin H, 210
Joe S-H, 196
Jones ME, 453
Jong-Yih L, 93
Joseph M, 609
Jun T-Y, 117
Jung B-J, 272
Jung H-G, 196
Jung S-M, 272
Jung S-W, 196

K

Kahn D, 186
Kahn RS, 288
Kalivas K, 186
Kamat S, 26
Kane JM, 409
Kaneko S, 408
Kang D-Y, 117
Kang R-H, 272
Kapur S, 571
Karagianis JL, 520
Karajgi B, 248
Karam RG, 614
Karmann M, 147
Kashima H, 394, 421
Katano T, 499
Katz MM, 198
Kawai N, 499
Keane S, 606
Keller F, 622
Kelsey D, 44
Kemp DE, 291
Kennedy SH, 157
Khanani S, 284
Khandrika S, 210
Kharasch E, 426
Khavidaki SD, 182
Khazaal Y, 192
Kiefer F, 99
Kiesel JL, 509
Kim C-E, 117
Kim DS, 561
Kim J-J, 117
Kim K-A, 272
Kim SH, 117
Kim S-H, 272
Kim Y-K, 272
Kim YS, 117
Kinon BJ, 278
Kirrane R, 565
Klaassen E, 124
Knezevic B, 319
Ko, MDY-H, 196
Kobak KA, 83, 409
Kobayashi H, 421
Koenigsberg HW, 396
Kollack-Walker S, 311
Kolluri S, 415
Konstantakopoulos G, 89, 300
Kors JA, 9
Koshikawa H, 421
Kouvelas D, 183
Kouzoupis AV, 300
Krams M, 412
Kranzler HR, 350
Kravitz E, 216
Krekels MM, 405
Kurtz DL, 278
Kusunoki M, 408

L

Laan W, 288
Lai I-C, 529
Laier SA, 611
Lammers CH, 170
Landen JW, 412
Landgrebe M, 618
Lane A, 606
Lane H-Y, 391
Lang UE, 611
Langbehn DR, 484
Langguth B, 618
Lanouette NM, 210
Larkin T, 606
Latham PK, 334
Lattanzi L, 504
Lee AH, 611
Lee C-H, 196
Lee D-K, 272
Lee E, 603
Lee KY, 117
Lee M-S, 196, 272
Leroy C, 86
Leserman A, 484
Letamendi AM, 561
Leuchter AF, 372
Leufkens TRM, 432
Leung C-M, 603
Leung M, 186
Levi R, 216
Levy-Mack H, 83
Lew Y-M, 196
Li Y, 378
Lieb M, 147
Lim P, 496
Lin C-C, 529
Lin H, 403
Lin N-C, 95
Linden M, 327
Liou Y-J, 529
Lipkovich IA, 311
Litta A, 504
Liu C-M, 616
Llorca P-M, 96
Lobello K, 383
Logan M, 492
Lombardo I, 26
Longobardi A, 504
Looij B-J, 405
Louik C, 555
Lovestone S, 387
Lungu C, 185
Lydiard B, 222

M

MacCormack-Gagnon J, 190
Machin D, 5
Malcolm R, 334
Mamo DC, 571
Mancino MJ, 488
Manjunatha N, 410
Manteghi A, 314
Manzanares J, 584
Mao JJ, 378, 478
Marcus RN, 362
Mark TL, 595
Martínez-Gras I, 584
Martinot J-L, 86
Mathias JL, 468
Matsunaga M, 619
Mattei MA, 358
Matthews JD, 73
McCarthy R, 248
McClure MM, 396
McCracken JT, 372
McGaugh J, 488
Meier CR, 134
Melkersson KI, 65
Menniti FS, 412
Menon M, 571
Merkl A, 170
Mezzalira L, 33
Micallef-Roll J, 548
Michalopoulou PG, 89
Milgrom PM, 426
Miller A, 444
Mitchell AA, 555
Mitchell AJ, 517
Mitzner S, 622
Mizuno M, 421
Molden E, 537
Moles A, 576
Möller H-J, 147
Montgomery SA, 409
Morena GP, 319
Morera AL, 97
Morgan CJA, 124
Morita K, 421
Morken G, 248
Morrato EH, 26
Mosini P, 343
Mudaliar S, 210
Mulder H, 16, 21
Mulsant BH, 571
Mutschler J, 99
Myrick H, 334

N

Nagaratnam M, 124
Nemoto K, 499
Neu P, 327
New A, 396
Newcomer JW, 26
Newton-Cheh C, 9
Nichols AI, 39, 383
Nolen WA, 513
Nordberg P, 302
Nosè M, 33
Nuamah IF, 496
Nwankwo V, 565

O

Ogunmefun A, 102
Oh K, 595
Okum F, 83
Olfson M, 307
Olié JP, 304
Oliveto A, 488

© 2009 Lippincott Williams & Wilkins

Oncken C, 350
Oneda B, 319
Opjordsmoen S, 109
Orman C, 239
Orr G, 216
Osorio I, 492
Osuala T, 102
Oulis P, 89, 300
Ozbilen M, 141

P

Pae C-U, 194
Palumbo J, 239
Papadimitriou GN, 89
Papageorgiou SG, 300
Papandonatos GD, 601
Papazisis G, 183
Park J-Y, 272
Park L, 73
Patrick AR, 590
Patroneva A, 39
Paul J, 39, 383
Paulsen JS, 484
Paulson H, 484
Pek E, 5
Penttilä J, 86
Perkins KA, 193
Perlis CS, 609
Perlis RH, 609
Perschel FH, 170
Petti TA, 201
Pfennig A, 327
Pfuhlmann B, 392
Pickrell JE, 426
Picon FA, 614
Pikalov A, 362
Poirier MF, 304
Pollock BG, 571
Pomara N, 312
Postel SC, 402
Praharaj SK, 189, 604
Pratt H, 444
Preskorn S, 39
Preskorn SH, 383, 412

Q

Quanbeck C, 186

R

Raisi F, 182
Raja M, 612
Rajji TK, 571
Ramaekers JG, 439
Randall PK, 334
Ravindran LN, 561
Raviv G, 216
Reed RC, 492
Refsum H, 537
Regenold WT, 102
Reiche I, 402
Reiser MF, 147
Reuter SC, 191
Reynolds D, 396
Rickels H, 174
Rickels K, 197
Riederer P, 392
Riva P, 343
Rizvi S, 157
Robinson DS, 197
Rockwell K, 378, 478
Roepke S, 170
Rohde LAP, 614
Rooney K, 73
Roose SP, 179, 216
Rose SA, 179
Rossell SL, 124
Rossi E, 33
Rossi P, 391
Roth T, 222
Rothman M, 496
Roumenov D, 86
Rubio G, 584
Russell JM, 96
Rutherford BR, 179

S

Sacco KA, 601
Saddichha S, 410
Sagman D, 520
Sakamoto K, 301
Salgado CAI, 614
Salgado-Pineda P, 548
Salmasi FB, 182
Salomoni G, 343
Sammel MD, 403
Sampson A, 496
Santos Filho A, 306
Sarkar S, 189, 604
Sartorius N, 409
Saunders EFH, 461
Saylor K, 44
Scheffer H, 16,
Schepis F, 576
Schiavi E, 504
Schmidtke A, 392
Schneeweiss S, 590
Schommer NC, 170
Schorr SG, 399
Schuh K, 44
Schwarcz G, 248
Scordo MG, 65
Seeger JD, 453
Seidman SN, 216
Selby P, 77, 231
Sentissi O, 304
Serretti A, 259
Setareh MJ, 182
Shad MU, 284
Shader RI, 317, 413
Sharma B, 165
Sharp I, 83
Sheehan D, 222
Sheng L, 403
Shepherd J, 503
Shih LC, 185
Shrivastava R, 222
Shults J, 378, 478
Siefert C, 73
Siever LJ, 396
Silber S, 239
Silk KR, 461
Silman H, 39
Silva KL, 614
Silverman J, 396
Sinha VK, 189, 604
Sirot EJ, 319
Sklarsky K, 73
Slooff CJ, 399
Smeets H, 288
Smolka MN, 327
Sneed JR, 179
Sniadecki J, 520
Soares J, 296
Soeller I, 378, 478
Sousa NO, 614
Spann M, 96
Sparve E, 302
Spencer T, 44, 239
Spielmans GI, 314
Spigset O, 248, 415
Spina E, 201
Sproule BA, 77, 231
St. John P, 497
Stange JP, 504
Starr HL, 239
Stauffer VL, 278
Stefanovic A, 124
Stein MB, 561
Stern RG, 201
Stewart SH, 334
Stolker JJ, 69
Straus SMJM, 9
Stricker BHC, 9
Strobl B, 509
Sturkenboom MCJM, 9
Su A, 186
Suárez-Antelo J, 310
Subramaniam M, 5
Sune Forsberg, 302
Sutton VK, 358, 520
Suzuki T, 394

T

Tahmatzidis D, 183
Takahashi S, 499
Takeshi K, 421
Takeuchi H, 394
Talamo A, 595
Tamayo JM, 358
Tanaka K, 619
Tansella M, 33
Tarsy D, 185
Tatebayashi H, 619
Tatulli A, 504
Taxis K, 399
Tay JAM, 5
Teipel SJ, 147
Tennen H, 350
Thase ME, 362
Theunissen EL, 439
Tiefenbach B, 622
Tobia A, 201
Toh S, 555
Tohen M, 358, 520
Tomasi MJ, 101
Tonn P, 191
Tran Q-V, 362
Trestman R, 396
Trichard C, 86
Tröger U, 402
Trzepacz PT, 44
Tsai AC, 91
Tsai P-C, 506
Tseng K-C, 398
Tsuruta T, 619
Tumas V, 306
Turnbull BR, 453
Tzellos T, 183

U

Uchida H, 394, 571
Ueki H, 619
Unglaub W, 618
Unterecker S, 392,
Uzun O, 620

V

van den Bergh D, 439
van den Broek WW, 513
van der Weide J, 21
van Geffen ECG, 69
van Megen HJ, 21
van Nieuwenhuizen AO, 73
van Noord C, 9
van Os E, 513
Velayudhan L, 387
Verkes RJ, 513
Vermeeren A, 432
Vessicchio JC, 601
Viala A, 304
Victor MM, 614
Vieta E, 358, 409
Vink R, 468
Vitola ES, 614

W

Waid R, 334
Wang PS, 590
Wang Y-C, 529
Watanabe K, 394
Weinberger AH, 193, 601
Weiser M, 216
Wells K, 83
Werler MM, 555
Wertenauer F, 611
Westin AA, 415
Wheaton P, 468
Wijkstra J, 513
Williams DW, 44
Williams JBW, 83
Willmund G, 611
Wilmink FW, 16
Wisniewski SR, 362
Witjas T, 548
Witteman JCM, 9
Wolf R, 402
Wright TM, 334
Wu Y, 609

Y

Yamada K, 301
Yamada S, 619
Yamazawa R, 421
Yang C, 619
Yang H, 362
Yao Y, 478
Yasui-Furukori N, 408

Z

Zahlsen K, 248
Zarate Jr. CA, 358
Zeni GD, 614
Ziegenhorn AA, 170
Zimmerman B, 239
Zoroglu S, 508
Zullino DF, 192
Zunta-Soares G, 296

© 2009 Lippincott Williams & Wilkins

Subject Index

A

γ-Aminobutyric acid (GABA) receptors
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: Relationship to alcohol withdrawal symptoms, Aug, 334

9-Hydroxyrisperidone
Effects of *CYP2D6* and *CYP3A5* genotypes on the plasma concentrations of risperidone and 9-Hydroxyrisperidone in Korean schizophrenic patients (brief report), June, 272
Impact of *CYP2D6* genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone, Dec, 537

5-Hydroxytryptamine (serotonin) receptor 2C (HTR2C)
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study, Feb, 16

ABCB1
ABCB1 and cytochrome p450 polymorphisms: Clinical pharmacogenetics of clozapine, Aug, 319

Acetylcholinesterase inhibitor
Combination therapy of acetylcholinesterase inhibitor and Vitamin E in Alzheimer disease (letter), Oct, 511

ADHD, *see* Attention-deficit/hyperactivity disorder (ADHD)

Adherence
Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics? Oct, 415

Adiponectin
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109

Adults
Atomoxetine and cerebrovascular outcomes in adults, Oct, 453
Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers, Feb, 39
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study, June, 239
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51
Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients, Feb, 26
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trial, Feb, 44
Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: Which strategy is better tolerated by adults with intellectual disabilities? (brief report), Oct, 492
Treatment of fetal alcohol spectrum disorders: Are we ready yet? (guest editorial), Feb, 1

Adverse effects
Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services, Dec, 565

Agomelatine
Sexual dysfunction, depression, and the impact of antidepressants, April, 157

Akaike's information criterion (AIC)
Does study design explain the relationship between conflict of interest and positive outcome in clinical trials in psychiatry? (letter), Dec, 609

Alcoholism
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: Relationship to alcohol withdrawal symptoms, Aug, 334
Modulation of impulsivity by topiramate implications for the treatment of alcohol dependence (brief report), Dec, 584

Alcohol pharmacotherapy
Targeted naltrexone for problem drinkers, Aug, 350

Algorithm-guided treatment
Efficacy of an algorithm-guided treatment compared with treatment as usual: A randomized, controlled study of inpatients with depression, Aug, 327

Allopregnanolone
Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms (letter), Aug, 403

Alternative medicine
A randomized, double-blind, placebo-controlled trial of oral *Matricaria recutita* (chamomile) extract therapy for generalized anxiety disorder (brief report), Aug, 378
Randomized, double-blind, placebo-controlled trial of *Cimicifuga racemosa* (Black cohosh) in women with anxiety disorder due to menopause (brief report), Oct, 478

Alzheimer disease
Combination therapy of acetylcholinesterase inhibitor and Vitamin E in Alzheimer disease (letter), Oct, 511
Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: A functional magnetic resonance imaging study, April, 147
Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil (brief report), Aug, 387

Amisulpride
Amisulpride treatment for clozapine-induced sialorrhea (letter), April, 189
Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls, April, 117
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics, Dec, 529
Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs, April, 141

Amygdala activity
Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease, Dec, 548

Amygdala atrophy
Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy (brief report), June, 284

Andropause
Effects of testosterone replacement in middle-aged men with dysthymia: A randomized, placebo-controlled clinical trial, June, 216

Angina
Health and economic burden of metabolic comorbidity among individuals with bipolar disorder (brief report), Dec, 595

Anticholinergic effects
Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs, April, 141

Antidepressants
Antidepressant drug prescription and risk of abnormal bleeding: A case-control study, Feb, 33
Antidepressants as hydrobromide salts: Are they a cause for concern? (editorial), Aug, 317
Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction, Dec, 555
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: An open-label cross-taper study, June, 206
Changes in neurocognitive function in patients with schizophrenia after

starting or switching to amisulpride in comparison with the normal controls, April, 117
Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective *N*-Methyl-D-aspartate antagonist, cp-101,606, in patients with treatment-refractory major deppressive disorder" (letter), Aug, 411
Comments on "Clinical trials of antidepressants: Time to shift to a new model?" (letter), April, 197
Delayed loss of efficacy and depressogenic action of antidepressants (letter), Dec, 612
Does the length of the first antidepressant treatment episode influence risk and time to a second episode? (brief report), Feb, 69
Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder (brief report), April, 174
Health advisories and patterns of patient monitoring among new users of antidepressant medications (brief report), Dec, 590
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109
Influence of antidepressant use on glycemic control in patients with diabetes mellitus: An open-label comparative study (letter), Aug, 405
Lithium effect on renal glomerular function in individuals with intellectual disability (brief report), June, 296
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: A pooled analysis of 2 studies (brief report), Aug, 362
Psychotropic drugs associated with corrected QT interval prolongation, Feb, 9
Reply to Drs Rickels and Robinson's comments on "Clinical trials of antidepressants: Time to shift to a new model?" (letter), April, 198
Reply to editorial "Antidepressants as hydrobromide salts: Are they a cause for concern?" (letter), Dec, 622
Sexual dysfunction, depression, and the impact of antidepressants, April, 157
Study design affects participant expectations: A survey (brief report), April, 179
Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis (review article), June, 259

Antipsychotics

Asymptomatic hyperamylasemia and hyperlipasemia associated with aripiprazole (letter), Oct, 504
Atypical neuroleptic malignant syndrome with quetiapine: A case report and review of the literature, Oct, 497.
Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls, April, 117
Clinical antipsychotic trials of intervention effectiveness study: A pragmatic trial? (letter), Aug, 410
Do antipsychotics cost lives or save lives? Risks versus benefits from large epidemiological studies (guest editorial), Dec, 517
Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics? Oct, 415
Ghrelin and leptin levels in patients with schizophrenia treated with antipsychotic monotherapy (letter), June, 304
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study, Feb, 16
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics, Dec, 529
Late-onset clozapine-induced hypothermia accompanied by electrocardiogram Osborn waves, 183
Lithium, antipsychotics, and risk of psoriasis, April, 134
Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients, Feb, 26
Onset and persistence of antipsychotic response in patients with schizophrenia, Dec, 542
Personality trait dimensions and the pharmacological treatment of borderline personality disorder, Oct, 464
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21
Prevalence and correlates of glucose monitoring in Chinese psychiatric patients on antipsychotics (letter), Dec, 603
Reply to comments on "Optimizing early prediction for antipsychotic response in schizophrenia" (letter), Aug, 391
Sexual dysfunction, depression, and the impact of antidepressants, April, 157
Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs, April, 141
Two patients with recurring syndrome of inappropriate secretion of antidiuretic hormone on multiple atypical antipsychotics (letter), April, 186

Anxiety disorder

A randomized, double-blind, placebo-controlled trial of oral *Matricaria recutita* (chamomile) extract therapy for generalized anxiety disorder (brief report), Aug, 378
Aripiprazole augmentation for a patient with partial remission of panic disorder (letter), June, 301
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study, June, 239
Evaluation of a urine on-site drugs of abuse screening test in patients admitted to a psychiatric emergency unit, June, 248
Questionable tolerability of tiagabine in generalized anxiety disorder (letter), June, 314
Randomized, double-blind, placebo-controlled trial of *Cimicifuga racemosa* (Black cohosh) in women with anxiety disorder due to menopause (brief report), Oct, 478

Apolipoprotein

Apolipoprotein E ε4: An understudied potential pharmacodynamic risk factor of drug-induced cognitive toxicity in the elderly (letter), June, 312
Response to the Letter by Dr Pomara on "Apolipoprotein E ε4: An understudied potential pharmacodynamic risk factor of drug-induced cognitive toxicity in the elderly" (letter), June, 313

Aripiprazole

A case of aripiprazole-associated paroxysmal supraventricular tachycardia (letter), Oct, 506
An open study of aripiprazole and escitalopram for psychotic major depressive disorder (brief report), Feb, 73
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients (brief report), April, 165
Aripiprazole augmentation for a patient with partial remission of panic disorder (letter), June, 301
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: An open-label cross-taper study, June, 206
Aripiprazole in refractory depression? (letter), Feb, 90
Asymptomatic hyperamylasemia and hyperlipasemia associated with aripiprazole (letter), Oct, 504
Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state, Oct, 421
Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state, Oct, 424
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: A pooled analysis of 2 studies (brief report), Aug, 362
Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: A 1-year naturalistic follow-up study (letter), Aug, 394
Reply to comments by Drs Carroll and Tsai regarding Marcus et al, Feb, 92
Successful aripiprazole augmentation in a child with drug-resistant

© 2009 Lippincott Williams & Wilkins

obsessive-compulsive disorder (letter), Dec, 607
Successful switch from clozapine to aripiprazole: A case report, Feb, 93
Tardive dyskinesia due to aripiprazole: Report of 2 cases (letter), April, 185
Two patients with recurring syndrome of appropriate secretion of antidiuretic hormone on multiple atypical antipschotics, April, 186
Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: Comments on article by Marcus et al (letter), Feb, 91
Waxing-and-waning catatonia after intermittent exposure to aripiprazole in a case of autism and bipolar disorder (letter), Oct, 503

Arrhythmia
Psychotropic drugs associated with corrected QT interval prolongation, Feb, 9

Aspirin
Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: A case report (letter), Oct, 509

Asymptomatic hyperamylasemia
Asymptomatic hyperamylasemia and hyperlipasemia associated with aripiprazole (letter), Oct, 504

Asymptomatic hyperlipasemia
Asymptomatic hyperamylasemia and hyperlipasemia associated with aripiprazole (letter), Oct, 504

Atomoxetine
A randomized controlled trial of atomoxetine in generalized social anxiety disorder, Dec, 561
Atomoxetine and cerebrovascular outcomes in adults, Oct, 453
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trial, Feb, 44
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease (brief report), Oct, 484
Treatment of fetal alcohol spectrum disorders: Are we ready yet? (guest editorial), Feb, 1

At-Risk Mental State
Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state, Oct, 421

Attention-deficit/hyperactivity disorder (ADHD)
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study, June, 239
National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder (letter), June, 307
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trial, Feb, 44
Treatment of fetal alcohol spectrum disorders: Are we ready yet? (guest editorial), Feb, 1

Attention deficits
D2 Receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia (brief report), Dec, 571

Atypical antidepressants
Bupropion-related parkinsonism and dystonia (letter), Dec, 616

Atypical antipsychotics
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics, Dec, 529

Atypical neuroleptic malignant syndrome
Atypical neuroleptic malignant syndrome with quetiapine: A case report and review of the literature (letter), Oct, 497

Auditory event-related potentials
Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect, Oct, 444

Autism spectrum disorder
National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder (letter), June, 307
Possible lamotrigine-induced mania in a child with autism spectrum disorder and epilepsy (letter), Oct, 508
Waxing-and-waning catatonia after intermittent exposure to aripiprazole in a case of autism and bipolar disorder (letter), Oct, 503

B

Bech-Rafaelsen Melancholia Scale (BRMS)
Efficacy of an algorithm-guided treatment compared with treatment as usual: A randomized, controlled study of inpatients with depression, Aug, 327

Behavior
Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease, Dec, 548
Effect of luteinizing hormone–releasing hormone agonists on behavior in a patient with dementia, Feb, 101
Impact of early immediate pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: A meta-analysis (review), Oct, 468
Predictors of abstinence and changes in psychiatric symptoms in a pooled sample of smokers with schizophrenia receiving combination pharmacotherapy and behavioral therapy for smoking cessation (letter), Dec, 601

Biases
Neuropsychiatric clinical trials: Should they accommodate real-world practices or set standards for clinical practices? Feb, 56

Bipolar depression
Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: An open-label, randomized, flexible-dose study in Puerto Rico (brief report), Aug, 358

Bipolar disorder (BD)
A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder, June, 291
Clozapine monotherapy for 66 months in treatment resistant bipolar disorder: A case report (letter), Oct, 501
Health and economic burden of metabolic comorbidity among individuals with bipolar disorder (brief report), Dec, 595
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder, Dec, 520
Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: Which strategy is better tolerated by adults with intellectual disabilities? (brief report), Oct, 492
Waxing-and-waning catatonia after intermittent exposure to aripiprazole in a case of autism and bipolar disorder (letter), Oct, 503

Bispectral index
Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers, Oct, 426

Bleeding abnormalities
Antidepressant drug prescription and risk of abnormal bleeding: A case-control study, Feb, 33

Blood pressure and pulse rate
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics, Dec, 529

Body weight
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics, Dec, 529

Books Received, Aug, 326

Borderline personality disorder
Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial (brief report), April, 170
Personality trait dimensions and the pharmacological treatment of borderline personality disorder, Oct, 461

Bruxism
Bruxism associated with serotonin reuptake inhibitors: Two cases (letter), Dec, 620

Bupropion
Abuse potential of bupropion nasal insufflation: A case report (letter), Dec, 618
Bupropion-related parkinsonism and dystonia (letter), Dec, 616

© 2009 Lippincott Williams & Wilkins

C

Cannabinoid hypothesis
Synthetic D-9-Tetrahydrocannabinol (Dronabinol) can improve the symptoms of schizophrenia, June, 255

Carbon dioxide
Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder (brief report), April, 174

Catatonia, waxing-and-waning
Waxing-and-waning catatonia after intermittent exposure to aripiprazole in a case of autism and bipolar disorder (letter), Oct, 503

Catecholamine reuptake inhibitor
Abuse potential of bupropion nasal insufflation: A case report (letter), Dec, 618

Catechol-o-methyltransferase (COMT)
Monoamine oxidase A and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder (brief report), Aug, 372

Centralized raters
Reply to comments by Grunze et al (letter), Aug, 409
Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia (letter), Aug, 409

Cerebrovascular disease
Atomoxetine and cerebrovascular outcomes in adults, Oct, 453

Chamomile
A randomized, double-blind, placebo-controlled trial of oral *Matricaria recutita* (chamomile) extract therapy for generalized anxiety disorder (brief report), Aug, 378

Children
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study, June, 239
National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder (letter), June, 307

Chinese psychiatric patients
Prevalence and correlates of glucose monitoring in Chinese psychiatric patients on antipsychotics (letter), Dec, 603

Cholesterol
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder, Dec, 520

Cholinergic treatment
Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: A functional magnetic resonance imaging study, April, 147

Cholinesterase inhibitors
Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil (brief report), Aug, 387

***Cimicifuga racemosa* (Black cohosh)**
Randomized, double-blind, placebo-controlled trial of *Cimicifuga racemosa* (Black cohosh) in women with anxiety disorder due to menopause (brief report), Oct, 478

Citalopram
Antidepressants as hydrobromide salts: Are they a cause for concern? (editorial), Aug, 317
Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response, Aug, 343

Clinical effects
Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers, Oct, 426

Clinical practice standards
Neuropsychiatric clinical trials: Should they accommodate real-world practices or set standards for clinical practices? Feb, 56

Clinical predictors
Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: A 1-year naturalistic follow-up study (letter), Aug, 394

Clinical significance
Reply to comments by Drs Carroll and Tsai regarding Marcus et al, Feb, 92
Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: Comments on article by Marcus et al (letter), Feb, 91

Clinical trials
A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive (brief report), June, 267
A randomized controlled trial of atomoxetine in generalized social anxiety disorder, Dec, 561
ABCB1 and cytochrome p450 polymorphisms: Clinical pharmacogenetics of clozapine, Aug, 319
Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction, Dec, 555
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: An open-label cross-taper study, June, 206
Does study design explain the relationship between conflict of interest and positive outcome in clinical trials in psychiatry? (letter), Dec, 609
Effects of testosterone replacement in middle-aged men with dysthymia: A randomized, placebo-controlled clinical trial, June, 216
Health advisories and patterns of patient monitoring among new users of antidepressant medications (brief report), Dec, 590
Impact of *CYP2D6* genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone, Dec, 537
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51
Mortality rates among patients with schizophrenia and tardive dyskinesia, Feb, 5
National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder (letter), June, 307
Neuropsychiatric clinical trials: Should they accommodate real-world practices or set standards for clinical practices? Feb, 56
Onset and persistence of antipsychotic response in patients with schizophrenia, Dec, 542
Open-label pilot study of modafinil for methamphetamine dependence (brief report), Oct, 488
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease (brief report), Oct, 484
Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia (letter), Aug, 409
Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services, Dec, 565
Sources of unreliability in depression ratings (brief report), Feb, 82
Study design affects participant expectations: A survey (brief report), April, 179

Clonidine
Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial (brief report), April, 170

Clozapine
ABCB1 and cytochrome p450 polymorphisms: Clinical pharmacogenetics of clozapine, Aug, 319
Acute clozapine intoxication (letter), June, 302
Amisulpride treatment for clozapine-induced sialorrhea (letter), April, 189
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients, April, 165
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65
Asymptomatic hyperamylasemia and hyperlipasemia associated with aripiprazole (letter), Oct, 504
Clozapine monotherapy for 66 months in treatment resistant bipolar disorder: A case report, Oct, 501
30 Days of continuous olanzapine infusion determines energy

© 2009 Lippincott Williams & Wilkins

imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice (brief report), Dec, 576
Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics? Oct, 415
Eosinophilic pleural effusion associated with the addition of sodium valproate (letter), June, 310
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study, Feb, 16
Increase in plasma levels of clozapine after addition of isoniazid, April, 189
Late-onset clozapine-induced hypothermia accompanied by electrocardiogram Osborn waves, April, 183
Management of clozapine-related hepatotoxicity (letter), Dec, 606
Olanzapine-induced "Restless Arms Syndrome" (letter), Feb, 89
Oral urea treatment for polydipsia-hyponatremia syndrome in patients with schizophrenia, Oct, 499
Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians (guest editorial), June, 201
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21
Remission of tardive dystonia with electroconvulsive therapy (letter), June, 314
Rhabdomyolysis following dose increase of clozapine and combination therapy with lithium (letter), Aug, 398
Successful switch from clozapine to aripiprazole: A case report, Feb, 93
Synthetic D-9-Tetrahydrocannabinol (Dronabinol) can improve the symptoms of schizophrenia, June, 255
Toxic clozapine serum levels during inflammatory reactions (letter), Aug, 392

Cocaine-disulfiram interaction
Pronounced paranoia as a result of cocaine-disulfiram interaction: Case report and mode of action, Feb, 99

Cognitive-behavioral therapy (CBT)
Bruxism associated with serotonin reuptake inhibitors: Two cases (letter), Dec, 620
Successful aripiprazole augmentation in a child with drug-resistant obsessive-compulsive disorder (letter), Dec, 607

Cognitive dysfunction
A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder, June, 291
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease (brief report), Oct, 484

Cognitive performance
D2 Receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia (brief report), Dec, 571
The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder (letter), Aug, 396
Highway driving in the elderly the morning after bedtime use of hypnotics: A comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo, Oct, 432
Impact of early immediate pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: A meta-analysis (review), Oct, 468

Combination therapy
Combination therapy of acetylcholinesterase inhibitor and Vitamin E in Alzheimer disease (letter), Oct, 511
Rhabdomyolysis following dose increase of clozapine and combination therapy with lithium (letter), Aug, 398

Comorbid insomnia
Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder, June, 222

Comorbidities
Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial (brief report), April, 170
Reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit/hyperactivity disorder: The role of comorbidities (letter), Dec, 614

Complementary medicine
A randomized, double-blind, placebo-controlled trial of oral *Matricaria recutita* (chamomile) extract therapy for generalized anxiety disorder (brief report), Aug, 378
Randomized, double-blind, placebo-controlled trial of *Cimicifuga racemosa* (Black cohosh) in women with anxiety disorder due to menopause (brief report), Oct, 478

Compliance
Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services, Dec, 565

Concomitant medications
A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive (brief report), June, 267

Conflict of interest
Does study design explain the relationship between conflict of interest and positive outcome in clinical trials in psychiatry? (letter), Dec, 609

Continuation treatment
Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: An open-label, randomized, flexible-dose study in Puerto Rico (brief report), Aug, 358

Corticosteroid therapy
Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy (brief report), June, 284

Cortisol
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109

Creatinine clearance
Lithium effect on renal glomerular function in individuals with intellectual disability (brief report), June, 296

CYP1A2
ABCB1 and cytochrome p450 polymorphisms: Clinical pharmacogenetics of clozapine, Aug, 319

CYP3A4
ABCB1 and cytochrome p450 polymorphisms: Clinical pharmacogenetics of clozapine, Aug, 319

CYP2C19
ABCB1 and cytochrome p450 polymorphisms: Clinical pharmacogenetics of clozapine, Aug, 319

CYP2D6
Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status (brief report), Aug, 383

***CYP2D6* genotype**
Impact of *CYP2D6* genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone, Dec, 537

Cytochrome P450 3A5 *(CYP3A5)*
Effects of *CYP2D6* and *CYP3A5* genotypes on the plasma concentrations of risperidone and 9-Hydroxyrisperidone in Korean schizophrenic patients (brief report), June, 272

Cytochrome P450 2D6 *(CYP2D6)*
Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers, Feb, 39
Effects of *CYP2D6* and *CYP3A5* genotypes on the plasma concentrations of risperidone and 9-Hydroxyrisperidone in Korean schizophrenic patients (brief report), June, 272
Trazodone hypnotic effect and nocturnal melatonin secretion, Feb, 97

D

Danzapine
Lithium, antipsychotics, and risk of psoriasis, April, 134

© 2009 Lippincott Williams & Wilkins

Dementia
Do antipsychotics cost lives or save lives? Risks versus benefits from large epidemiological studies (guest editorial), Dec, 517
Effect of luteinizing hormone–releasing hormone agonists on behavior in a patient with dementia, Feb, 101

Demographic variables
Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services, Dec, 565

Depression
Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction, Dec, 555
Does the length of the first antidepressant treatment episode influence risk and time to a second episode? (brief report), Feb, 69
Efficacy of an algorithm-guided treatment compared with treatment as usual: A randomized, controlled study of inpatients with depression, Aug, 327
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51
Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients, Feb, 26
Sources of unreliability in depression ratings (brief report), Feb, 82
Study design affects participant expectations: A survey (brief report), April, 179

Depressogenic action
Delayed loss of efficacy and depressogenic action of antidepressants (letter), Dec, 612

Desvenlafaxine
Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers, Feb, 39
Does the length of the first antidepressant treatment episode influence risk and time to a second episode? (brief report), Feb, 69

Dextromethorphan/quinidine effects
Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect, Oct, 444

Diabetes
Health and economic burden of metabolic comorbidity among individuals with bipolar disorder (brief report), Dec, 595
Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients, Feb, 26

Diabetes mellitus
Influence of antidepressant use on glycemic control in patients with diabetes mellitus: An open-label comparative study (letter), Aug, 405

Dialysis
Dialysis-associated increase in the saliva level of paroxetine (letter), Dec, 619

Divalproex
Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: Which strategy is better tolerated by adults with intellectual disabilities? (brief report), Oct, 492

Donepezil
Effect of donepezil on tardive dyskinesia (letter), Feb, 102
Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil (brief report), Aug, 387

Dopamine
D2 Receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia (brief report), Dec, 571
Monoamine oxidase A and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder (brief report), Aug, 372

Dopaminergic system
Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease, Dec, 548

Dorsal visual pathway
Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: A functional magnetic resonance imaging study, April, 147

D2 receptor blockade
D2 Receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia (brief report), Dec, 571

Dronabinol, *see* **Synthetic D-9-Tetrahydrocannabinol**

Drug-induced cognitive toxicity
Apolipoprotein E ε4: An understudied potential pharmacodynamic risk factor of drug-induced cognitive toxicity in the elderly (letter), June, 312
Response to the Letter by Dr Pomara on "Apolipoprotein E ε4: An understudied potential pharmacodynamic risk factor of drug-induced cognitive toxicity in the elderly" (letter), June, 313

Drug–placebo differences
Does study design explain the relationship between conflict of interest and positive outcome in clinical trials in psychiatry? (letter), Dec, 609

Drug resistance
Successful aripiprazole augmentation in a child with drug-resistant obsessive-compulsive disorder (letter), Dec, 607

Duloxetine
A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: Implications for the randomized withdrawal relapse prevention study design, Feb, 96
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51

Dyslipidemia
30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice (brief report), Dec, 576
Health and economic burden of metabolic comorbidity among individuals with bipolar disorder (brief report), Dec, 595
Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients, Feb, 26

Dysthymia
Effects of testosterone replacement in middle-aged men with dysthymia: A randomized, placebo-controlled clinical trial, June, 216

Dystonia
Bupropion-related parkinsonism and dystonia (letter), Dec, 616

E

Economic burden
Health and economic burden of metabolic comorbidity among individuals with bipolar disorder (brief report), Dec, 595

Editorials
An irreverent look at the *t* test, (guest editorial), April, 105
Antidepressants as hydrobromide salts: Are they a cause for concern? (editorial), Aug, 317
The cart before the horse? Health insurance reform before health care reform (editorial), Oct, 413
Do antipsychotics cost lives or save lives? Risks versus benefits from large epidemiological studies (guest editorial), Dec, 517
Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians (guest editorial), June, 201
Treatment of fetal alcohol spectrum disorders: Are we ready yet? (guest editorial), Feb, 1

Effect duration
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder, Feb, 44

Efficacy loss
Delayed loss of efficacy and depressogenic action of antidepressants (letter), Dec, 612

Elderly patients
Apolipoprotein E ε4: An understudied potential pharmacodynamic risk factor of drug-induced cognitive toxicity in the elderly (letter), June, 312

© 2009 Lippincott Williams & Wilkins

D2 Receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia (brief report), Dec, 571
Effects of testosterone replacement in middle-aged men with dysthymia: A randomized, placebo-controlled clinical trial, June, 216
Highway driving in the elderly the morning after bedtime use of hypnotics: A comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo, Oct, 432
Response to the Letter by Dr Pomara on "Apolipoprotein E ε4: An understudied potential pharmacodynamic risk factor of drug-induced cognitive toxicity in the elderly" (letter), June, 313

Electrocardiography
Psychotropic drugs associated with corrected QT interval prolongation, Feb, 9

Electroconvulsive therapy
Remission of tardive dystonia with electroconvulsive therapy (letter), June, 314

Emotion
Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease, Dec, 548

Endocannabinoid stimulation
Synthetic D-9-Tetrahydrocannabinol (Dronabinol) can improve the symptoms of schizophrenia, June, 255

Energy expenditure
30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice (brief report), Dec, 576

Eosinophilia
Eosinophilic pleural effusion associated with the addition of sodium valproate (letter), June, 310

Epidemiological studies
Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction, Dec, 555
Do antipsychotics cost lives or save lives? Risks versus benefits from large epidemiological studies (guest editorial), Dec, 517

Epilepsy
Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: Which strategy is better tolerated by adults with intellectual disabilities? (brief report), Oct, 492
Possible lamotrigine-induced mania in a child with autism spectrum disorder and epilepsy (letter), Oct, 508

Episode relapse
Does the length of the first antidepressant treatment episode influence risk and time to a second episode? (brief report), Feb, 69

Epworth Sleepiness Scale
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: Relationship to alcohol withdrawal symptoms, Aug, 334

Errata, 38, 55, 169, 221

Escitalopram
An open study of aripiprazole and escitalopram for psychotic major depressive disorder (brief report), Feb, 73
Antidepressant drug prescription and risk of abnormal bleeding: A case-control study, Feb, 33
Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder (brief report), April, 174
Mean platelet volume in patients with major depression: Effect of escitalopram treatment (brief report), Aug, 368
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51
Sexual dysfunction, depression, and the impact of antidepressants, April, 157
Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder, June, 222

Expectancy
Study design affects participant expectations: A survey (brief report), April, 179

Extensive metabolizers
Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status (brief report), Aug, 383

F

Fetal alcohol spectrum disorders (FASD)
Treatment of fetal alcohol spectrum disorders: Are we ready yet? (guest editorial), Feb, 1

Fetal growth
Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction, Dec, 555

Fexofenadine
Comparing the stimulant effects of the H1-antagonist fexofenadine with 2 psychostimulants, modafinil and methylphenidate, Oct, 439

Flumazenil
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: Relationship to alcohol withdrawal symptoms, Aug, 334

Fluoxetine
Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: An open-label, randomized, flexible-dose study in Puerto Rico (brief report), Aug, 358
Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians (guest editorial), June, 201
Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis (review article), June, 259
Trismus induced by fluoxetine (letter), June, 306

Functional magnetic resonance imaging (fMRI)
Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease, Dec, 548

G

Gabapentin
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: Relationship to alcohol withdrawal symptoms, Aug, 334

Galantamine
A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder, June, 291
Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer isease: A functional magnetic resonance imaging study, April, 147

Gastrointestinal bleeding
Antidepressant drug prescription and risk of abnormal bleeding: A case-control study, Feb, 33

Gene polymorphisms
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study, Feb, 16

Generalized anxiety disorder (GAD)
A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: Implications for the randomized withdrawal relapse prevention study design, Feb, 96
A randomized, double-blind, placebo-controlled trial of oral *Matricaria recutita* (chamomile) extract therapy for generalized anxiety disorder (brief report), Aug, 378
Bruxism associated with serotonin reuptake inhibitors: Two cases (letter), Dec, 620
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51
Methadone-nicotine interactions in methadone maintenance treatment patients, June, 231
Questionable tolerability of tiagabine in generalized anxiety disorder (letter), June, 314
Zolpidem extended-release improves sleep and next-day symptoms in

© 2009 Lippincott Williams & Wilkins

comorbid insomnia and generalized anxiety disorder, June, 222

Genetic polymorphisms
Monoamine oxidase A and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder (brief report), Aug, 372

German Algorithm Project (GAP)
Efficacy of an algorithm-guided treatment compared with treatment as usual: A randomized, controlled study of inpatients with depression, Aug, 327

Ghrelin
Ghrelin and leptin levels in patients with schizophrenia treated with antipsychotic monotherapy (letter), June, 304

Glucocorticosteroids
Glucocorticosteroids associated with a decreased risk of psychosis (brief report), June, 288

Glucose intolerance
30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice (brief report), Dec, 576

Glucose metabolism
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics, Dec, 529

Glucose monitoring
Prevalence and correlates of glucose monitoring in Chinese psychiatric patients on antipsychotics (letter), Dec, 603

Glucose tolerance test
30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice (brief report), Dec, 576

Glutamate hypofunction
Acute and chronic effects of ketamine on semantic priming: Modeling schizophrenia? April, 124

Glycemic control
Influence of antidepressant use on glycemic control in patients with diabetes mellitus: An open-label comparative study (letter), Aug, 405

H

Hallucinations
Hallucinations associated with modafinil treatment for narcolepsy (letter), Aug, 408

Hamilton Depression Scale, Feb, 82

H1-antagonist fexofenadine
Comparing the stimulant effects of the H1-antagonist fexofenadine with 2 psychostimulants, modafinil and methylphenidate, Oct, 439

Health care
The cart before the horse? Health insurance reform before health care reform (editorial), Oct, 413
Health advisories and patterns of patient monitoring among new users of antidepressant medications (brief report), Dec, 590
Health and economic burden of metabolic comorbidity among individuals with bipolar disorder (brief report), Dec, 595

Hepatotoxicity
Management of clozapine-related hepatotoxicity (letter), Dec, 606

Highway driving
Highway driving in the elderly the morning after bedtime use of hypnotics: A comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo, Oct, 432

Hormonal markers
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109

HTR2A
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65

HTR2C, *see* **5-hydroxytryptamine (serotonin) receptor 2C**

Huntington disease
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease (brief report), Oct, 484

Hydrobromide salts, *see also* **Citalopram**
Antidepressants as hydrobromide salts: Are they a cause for concern? (editorial), Aug, 317
Reply to editorial "Antidepressants as hydrobromide salts: Are they a cause for concern?" (letter), Dec, 622

Hyperamylasemia
Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: A case report (letter), Aug, 391

Hyperarousal
Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial (brief report), April, 170

Hyperlipasemia
Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: A case report (letter), Aug, 391

Hypertension
Health and economic burden of metabolic comorbidity among individuals with bipolar disorder (brief report), Dec, 595

Hypnotics
Highway driving in the elderly the morning after bedtime use of hypnotics: A comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo, Oct, 432
Trazodone hypnotic effect and nocturnal melatonin secretion, Feb, 97

Hypogonadism
Effects of testosterone replacement in middle-aged men with dysthymia: A randomized, placebo-controlled clinical trial, June, 216

Hypothermia
Late-onset clozapine-induced hypothermia accompanied by electrocardiogram Osborn waves (letter), April, 183

I

Impulsivity modulation
Modulation of impulsivity by topiramate implications for the treatment of alcohol dependence (brief report), Dec, 584

Inflammatory reactions
Toxic clozapine serum levels during inflammatory reactions (letter), Aug, 392

Insomnia Severity Index
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: Relationship to alcohol withdrawal symptoms, Aug, 334

Insulin
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109

Insulin resistance
30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice (brief report), Dec, 576

Intellectual disability
Lithium effect on renal glomerular function in individuals with intellectual disability (brief report), June, 296
Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: Which strategy is better tolerated by adults with intellectual disabilities? (brief report), Oct, 492

Isoniazid
Increase in plasma levels of clozapine after addition of isoniazid (letter), April, 190

K

Ketamine
Acute and chronic effects of ketamine on semantic priming: Modeling schizophrenia?, April, 124

Kidney
Lithium effect on renal glomerular function in individuals with intellectual disability (brief report), June, 296

L

Lamotrigine
A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized

© 2009 Lippincott Williams & Wilkins

and partially responsive (brief report), June, 267
Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy (brief report), June, 284
Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians (guest editorial), June, 201
Possible lamotrigine-induced mania in a child with autism spectrum disorder and epilepsy (letter), Oct, 508

LEP- and LEPR gene
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21

Leptin
Ghrelin and leptin levels in patients with schizophrenia treated with antipsychotic monotherapy (letter), June, 304
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21

Leptin resistance
30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice (brief report), Dec, 576

Levomethadone
Levomethadone is poorly removed by the molecular adsorbents recirculating system (letter), Dec, 622

Lipid metabolism
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients (brief report), April, 165

Lithium
Lithium, antipsychotics, and risk of psoriasis, April, 134
Lithium effect on renal glomerular function in individuals with intellectual disability (brief report), June, 296
Rhabdomyolysis following dose increase of clozapine and combination therapy with lithium (letter), Aug, 398
Sexual dysfunction,depression and the impact of antidepressants, April, 157
Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services, Dec, 565
Treatment of unipolar psychotic depression: An open study of lithium addition in refractory psychotic depression (letter), Oct, 513

Logistic regression
Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response, Aug, 343

Luteinizing hormone agonists
Effect of luteinizing hormone–releasing hormone agonists on behavior in a patient with dementia, Feb, 101

M

MADRS, *see* **Montgomery–Asberg Depression Scale**

Magnetic resonance imaging (MRI)
Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: A functional magnetic resonance imaging study, April, 147
Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease, Dec, 548

Major depressive disorders
An open study of aripiprazole and escitalopram for psychotic major depressive disorder (brief report), Feb, 73
Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective *N*-Methyl-D-aspartate antagonist, cp-101,606, in patients with treatment-refractory major deppressive disorder" (letter), 411
Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients (brief report), Feb, 77
Mean platelet volume in patients with major depression: Effect of escitalopram treatment (brief report), Aug, 368
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: A pooled analysis of 2 studies (brief report), Aug, 362
Monoamine oxidase A and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder (brief report), Aug, 372
Reply to comments by Drs Carroll and Tsai regarding Marcus et al, Feb, 92
Sexual dysfunction, depression and the impact of antidepressants, April, 157
Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: Comments on article by Marcus et al (letter), Feb, 91

Matricaria recutita
A randomized, double-blind, placebo-controlled trial of oral *Matricaria recutita* (chamomile) extract therapy for generalized anxiety disorder (brief report), Aug, 378

Mattis Dementia Rating Scale
Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease, Dec, 548

Mean platelet volume
Mean platelet volume in patients with major depression: Effect of escitalopram treatment (brief report), Aug, 368

Medical morbidity
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients (brief report), April, 165

Medication
Modulation of impulsivity by topiramate implications for the treatment of alcohol dependence (brief report), Dec, 584
Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services, Dec, 565

Meeting Notice, Aug, 342

Melatonin, nocturnal secretion
Trazodone hypnotic effect and nocturnal melatonin secretion, Feb, 97

Memantine augmentation
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51

Menopause
Randomized, double-blind, placebo-controlled trial of *Cimicifuga racemosa* (Black cohosh) in women with anxiety disorder due to menopause (brief report), Oct, 478

Metabolic comorbidity
Health and economic burden of metabolic comorbidity among individuals with bipolar disorder (brief report), Dec, 595

Metabolic dysregulation
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109

Metabolic outcomes
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics, Dec, 529

Metabolic profile
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: A pooled analysis of 2 studies (brief report), Aug, 362

Metabolic risk status
Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients, Feb, 26

Metabolic syndrome
An open study of aripiprazole and escitalopram for psychotic major depressive disorder (brief report), Feb, 73
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic

© 2009 Lippincott Williams & Wilkins

abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65
Association of posttraumatic stress disorder with increased prevalence of metabolic syndrome, June, 210
30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice (brief report), Dec, 576
Ghrelin and leptin levels in patients with schizophrenia treated with antipsychotic monotherapy (letter), June, 304
Health and economic burden of metabolic comorbidity among individuals with bipolar disorder (brief report), Dec, 595
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study, Feb, 16
Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients, Feb, 26
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21
Prevalence of metabolic syndrome in patients with psychotic disorders in the Netherlands (letter), Aug, 399

Methadone
Evaluation of a urine on-site drugs of abuse screening test in patients admitted to a psychiatric emergency unit, June, 248
Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients (brief report), Feb, 77
Methadone-Nicotine interactions in methadone maintenance treatment patients, June, 231

Methadone-Nicotine interactions
Methadone-Nicotine interactions in methadone maintenance treatment patients, June, 231

Methamphetamine
Open-label pilot study of modafinil for methamphetamine dependence (brief report), Oct, 488

Methylphenidate
Comparing the stimulant effects of the H1-antagonist fexofenadine with 2 psychostimulants, modafinil and methylphenidate, Oct, 439
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study, June, 239
Evaluation of a urine on-site drugs of abuse screening test in patients admitted to a psychiatric emergency unit, June, 248
Reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit/hyperactivity disorder: The role of comorbidities (letter), Dec, 614

Mini-Mental State Examination (MMSE)
D2 Receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia (brief report), Dec, 571

Mirtazapine
High mirtazapine plasma levels in infant after breast feeding: Case report and review of the literature (letter), April, 191
Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services, Dec, 565

Modafinil
Comparing the stimulant effects of the H1-antagonist fexofenadine with 2 psychostimulants, modafinil and methylphenidate, Oct, 439
Hallucinations associated with modafinil treatment for narcolepsy (letter), Aug, 408
Open-label pilot study of modafinil for methamphetamine dependence (brief report), Oct, 488

Molecular Adsorbents Recirculating System (MARS)
Levomethadone is poorly removed by the molecular adsorbents recirculating system (letter), Dec, 622

Monoamine oxidase A (MAO-A)
Cerebral monoamine oxidase a inhibition in tobacco smokers confirmed with PET and [11C]Befloxatone (brief report), Feb, 86
Monoamine oxidase A and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder (brief report), Aug, 372

Montgomery-Åsberg Depression Rating Scale (MADRS)
Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease, Dec, 548
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51

Mood stabilizers
A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive (brief report), June, 267
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: An open-label cross-taper study, June, 206
Ghrelin and leptin levels in patients with schizophrenia treated with antipsychotic monotherapy (letter), June, 304

Mortality rates
Mortality rates among patients with schizophrenia and tardive dyskinesia, Feb, 5

Multiple atypical antipsychotics
Two patients with recurring syndrome of inappropriate secretion of antidiuretic hormone on multiple atypical antipsychotics (letter), April, 186

Multiple sclerosis
Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect, Oct, 444

Myopathy
Valproic acid-induced myopathy in a patient with schizoaffective disorder (letter), Aug, 402

N

Naltrexone
Targeted naltrexone for problem drinkers, Aug, 350

Narcolepsy
Hallucinations associated with modafinil treatment for narcolepsy (letter), Aug, 408

Nasal insufflation
Abuse potential of bupropion nasal insufflation: A case report (letter), Dec, 618

National Cholesterol Education Program's Adult Treatment Panel III
Psychotropic drugs associated with corrected QT interval prolongation, Feb, 9

Neural networks
Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response, Aug, 343

Neurocognitive function
Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls, April, 117

Neuroleptic malignant syndrome
Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: A case report (letter), Aug, 391

Neuropsychiatry
Neuropsychiatric clinical trials: Should they accommodate real-world practices or set standards for clinical practices?, Feb, 56
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder, Feb, 44
Treatment of fetal alcohol spectrum disorders: Are we ready yet? (guest editorial), Feb, 1

Neuropsychological assessment
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease (brief report), Oct, 484

NMDA receptor
Acute and chronic effects of ketamine on semantic priming: Modeling schizophrenia? April, 124

***N*-Methyl-D-aspartate antagonist**
Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective

© 2009 Lippincott Williams & Wilkins

N-Methyl-D-aspartate antagonist, cp-101,606, in patients with treatment-refractory major deppressive disorder" (letter), Aug, 411
Reply to Comments by Dr Hashimoto (letter), Aug, 412

Nonfasting glucose
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder, Dec, 520

Norepinephrine
Monoamine oxidase A and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder (brief report), Aug, 372

Number-needed-to-harm (NNH)
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder, Dec, 520

Number-needed-to-treat (NNT)
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder, Dec, 520

O

Obesity
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients (brief report), April, 165
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzipinetreatment under real-life conditions, April, 109
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study, Feb, 16
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics, Dec, 529
Mortality rates among patients with schizophrenia and tardive dyskinesia, Feb, 5
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21

Obsessive-compulsive disorder (OCD)
Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response, Aug, 343
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51
Successful aripiprazole augmentation in a child with drug-resistant obsessive-compulsive disorder (letter), Dec, 607

Oculogyric crisis
Olanzapine-induced tardive oculogyric crisis (letter), Dec, 604

O-desmethylvenlafaxine
Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status (brief report), Aug, 383

OGTT, *see* **Glucose tolerance test**

Olanzapine
An open study of aripiprazole and escitalopram for psychotic major depressive disorder, Feb, 73
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients (brief report), April, 165
Aripiprazole augmentation for a patient with partial remission of panic disorder (letter), June, 301
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: An open-label cross-taper study, June, 206
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65
Association of posttraumatic stress disorder with increased prevalence of metabolic syndrome, June, 210
Changes in neurocognitive functions in patients with schizophrenia after starting or switching to amisulpride in comparison with normal controls, April, 117
Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzipine (letter), April, 182
30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice (brief report), Dec, 576
Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics? Oct, 415
Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: An open-label, randomized, flexible-dose study in Puerto Rico (brief report), Aug, 358
Ghrelin and leptin levels in patients with schizophrenia treated with antipsychotic monotherapy (letter), June, 304
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study, Feb, 16
Late-onset clozapine-induced hypothermia accompanied by electrocardiogram Osborn waves, April, 183
Lithium, antipsychotics, and risk of psoriasis, April, 134
Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients, Feb, 26
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder, Dec, 520
Olanzapine-induced "Restless Arms Syndrome" (letter), Feb, 89
Olanzapine-induced tardive oculogyric crisis (letter), Dec, 604
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: An analysis of correlations with efficacy, weight gain, and prolactin concentration (brief report), June, 278
Personality trait dimensions and the pharmacological treatment of borderline personality disorder, Oct, 464
Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians (guest editorial), June, 201
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21
Psychotropic drugs associated with corrected QT interval prolongation, Feb, 9
Sexual dysfunction, depression and the impact of antidepressants, April, 157
Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services, Dec, 565
Successful switch from clozapine to aripiprazole: A case report, Feb, 93
Synthetic D-9-Tetrahydrocannabinol (Dronabinol) can improve the symptoms of schizophrenia, June, 255
Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs, April, 141

Olanzapine/fluoxetine combination
Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: An open-label, randomized, flexible-dose study in Puerto Rico (brief report), Aug, 358

Opioid withdrawal
Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients (brief report), Feb, 77

Oral urea treatment
Oral urea treatment for polydipsia-hyponatremia syndrome in patients with schizophrenia (letter), Oct, 499

P

Paliperidone ER
Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: A mediation analysis (letter), Oct, 496
Onset and persistence of antipsychotic response in patients with schizophrenia, Dec, 542

Panic disorder
Aripiprazole augmentation for a patient with partial remission of panic disorder (letter), June, 301

© 2009 Lippincott Williams & Wilkins

Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder (brief report), April, 174

PANSS, *see* Positive and Negative Syndromes Scale

Paranoia
Pronounced paranoia as a result of cocaine-disulfiram interaction: Case report and mode of action, Feb, 99
Successful switch from clozapine to aripiprazole: A case report, Feb, 93

Parkinson disease (PD)
Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease, Dec, 548

Paroxetine
Dialysis-associated increase in the saliva level of paroxetine (letter), Dec, 619

Paroxysmal supraventricular tachycardia
A case of aripiprazole-associated paroxysmal supraventricular tachycardia (letter), Oct, 506

Patient monitoring
Health advisories and patterns of patient monitoring among new users of antidepressant medications (brief report), Dec, 590

Patients' insurance
Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients, Feb, 26

PD, *see* Parkinson disease (PD)

Personality disorder
Personality trait dimensions and the pharmacological treatment of borderline personality disorder, Oct, 464

Personality trait dimensions
Personality trait dimensions and the pharmacological treatment of borderline personality disorder, Oct, 461

PET, *see* Positron emission tomography

Pharmacoepidemiology
Does the length of the first antidepressant treatment episode influence risk and time to a second episode? (brief report), Feb, 69

Pharmacogenetics
Effects of *CYP2D6* and *CYP3A5* genotypes on the plasma concentrations of risperidone and 9-Hydroxyrisperidone in Korean schizophrenic patients (brief report), June, 272
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21

Pharmacokinetics
Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers, Feb, 39
Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers, Oct, 426
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: An analysis of correlations with efficacy, weight gain, and prolactin concentration (brief report), June, 278
Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians (guest editorial), June, 201

Pharmacokinetics–pharmacodynamics
Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients (brief report), Feb, 77

Pharmacological heterogeneity
Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians (guest editorial), June, 201

Pharmacological management
National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder (letter), June, 307

Pharmacological MRI
Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: A functional magnetic resonance imaging study, April, 147

Pharmacological treatment
Impact of early immediate pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: A meta-analysis (review), Oct, 468
Personality trait dimensions and the pharmacological treatment of borderline personality disorder, Oct, 464

Pharmacotherapy
A randomized controlled trial of atomoxetine in generalized social anxiety disorder, Dec, 561
Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial (brief report), April, 170
Personality trait dimensions and the pharmacological treatment of borderline personality disorder, Oct, 461
Predictors of abstinence and changes in psychiatric symptoms in a pooled sample of smokers with schizophrenia receiving combination pharmacotherapy and behavioral therapy for smoking cessation (letter), Dec, 601
Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder, June, 222

Photoallergic reaction
Sertraline-induced photoallergic reaction, Feb, 95

Placebo control
Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder (brief report), April, 174
Study design affects participant expectations: A survey (brief report), April, 179

Placebo response
Monoamine oxidase A and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder (brief report), Aug, 372

Plasma concentration
ABCB1 and cytochrome p450 polymorphisms: Clinical pharmacogenetics of clozapine, Aug, 319

Platelet activity
Mean platelet volume in patients with major depression: Effect of escitalopram treatment (brief report), Aug, 368

Pleural effusion
Eosinophilic pleural effusion associated with the addition of sodium valproate (letter), June, 310

Polydipsia-hyponatremia syndrome
Oral urea treatment for polydipsia-hyponatremia syndrome in patients with schizophrenia (letter), Oct, 499

Polymorphisms
ABCB1 and cytochrome p450 polymorphisms: Clinical pharmacogenetics of clozapine, Aug, 319
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65
Monoamine oxidase A and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder (brief report), Aug, 372
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21

Poor metabolizers
Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status (brief report), Aug, 383

Positive and Negative Syndrome Scale (PANSS)
Onset and persistence of antipsychotic response in patients with schizophrenia, Dec, 542

Positive outcomes
Does study design explain the relationship between conflict of interest and positive outcome in clinical trials in psychiatry? (letter), Dec, 609

Positron emisssion tomography (PET)
Cerebral monoamine oxidase a inhibition in tobacco smokers confirmed with PET and [^{11}c]Befloxatone (brief report), Feb, 86

Posttraumatic stress disorder (PTSD)
Association of posttraumatic stress disorder with increased prevalence of metabolic syndrome, June, 210

Practice effects
Changes in neurocognitive functions in patients with schizophrenia after

© 2009 Lippincott Williams & Wilkins

starting or switching to amisulpride in comparison with normal controls, April, 117

Prediction optimization
Reply to comments on "optimizing early prediction for antipsychotic response in schizophrenia" (letter), Aug, 391

Pregnancy
Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction, Dec, 555

Premenstrual symptoms
Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms (letter), Aug, 403

Preterm delivery risk
Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction, Dec, 555

Pretreatment attrition
Reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit/hyperactivity disorder: The role of comorbidities (letter), Dec, 614

Previsional models
Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response, Aug, 343

Problem drinkers
Targeted naltrexone for problem drinkers, Aug, 350

Prodrome
Effects of aripiprazole on insight and subjective experiencein individuals with an at risk mental state, Oct, 421

Prolactin concentration
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: An analysis of correlations with efficacy, weight gain, and prolactin concentration (brief report), June, 278

Prometa protocol
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: Relationship to alcohol withdrawal symptoms, Aug, 334

Propensity scores
Atomoxetine and cerebrovascular outcomes in adults, Oct, 453

Protocol standards
Neuropsychiatric clinical trials: Should they accommodate real-world practices or set standards for clinical practices? Feb, 56

Pseudobulbar affect
Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect, Oct, 444

Psoriasis
Lithium, antipsychotics, and risk of psoriasis, April, 134

Psychiatric disorders
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics, Dec, 529
Reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit/hyperactivity disorder: The role of comorbidities (letter), Dec, 614
Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services, Dec, 565

Psychiatric Emergency Unit
Evaluation of a urine on-site drugs of abuse screening test in patients admitted to a psychiatric emergency unit, June, 248

Psychiatric symptom changes
Predictors of abstinence and changes in psychiatric symptoms in a pooled sample of smokers with schizophrenia receiving combination pharmacotherapy and behavioral therapy for smoking cessation (letter), Dec, 601

Psychiatry
Does study design explain the relationship between conflict of interest and positive outcome in clinical trials in psychiatry? (letter), Dec, 609
Personality trait dimensions and the pharmacological treatment of borderline personality disorder, Oct, 461

Psychomotor performance
Comparing the stimulant effects of the H1-antagonist fexofenadine with 2 psychostimulants, modafinil and methylphenidate, Oct, 439
Highway driving in the elderly the morning after bedtime use of hypnotics: A comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo, Oct, 432

Psychosis
An open study of aripiprazole and escitalopram for psychotic major depressive disorder, Feb, 73
Association of posttraumatic stress disorder with increased prevalence of metabolic syndrome, June, 210
Effects of aripiprazole on insight and subjective experience in individuals with an at risk mental state, Oct, 421
Glucocorticosteroids associated with a decreased risk of psychosis (brief report), June, 288
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study, Feb, 16
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21
Prevalence of metabolic syndrome in patients with psychotic disorders in the Netherlands (letter), Aug, 399

Psychostimulant
Comparing the stimulant effects of the H1-antagonist fexofenadine with 2 psychostimulants, modafinil and methylphenidate, Oct, 439

Psychotropic drugs
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65
Psychotropic drugs associated with corrected QT interval prolongation, Feb, 9

Putative neuroleptic malignant syndrome
Putative neuroleptic malignant syndrome associated with sertraline withdrawal (letter), June, 300

Q

QT interval prolongation
Psychotropic drugs associated with corrected QT interval prolongation, Feb, 9

Quetiapine
Atypical neuroleptic malignant syndrome with quetiapine: A case report and review of the literature (letter), Oct, 497

Quitkin methodology
Onset and persistence of antipsychotic response in patients with schizophrenia, Dec, 542

R

Real-world practices
Neuropsychiatric clinical trials: Should they accommodate real-world practices or set standards for clinical practices? Feb, 56

Receptors
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65

Refractory depression
Aripiprazole in refractory depression? (letter), Feb, 90
Treatment of unipolar psychotic depression: An open study of lithium addition in refractory psychotic depression (letter), Oct, 513

Relapse prevention
A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: Implications for the randomized withdrawal relapse prevention study design, Feb, 96

Renal glomerular function
Lithium effect on renal glomerular function in individuals with intellectual disability (brief report), June, 296

Responder analysis
A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: Implications for the randomized withdrawal relapse prevention study design, Feb, 96

Response patterns
Onset and persistence of antipsychotic response in patients with schizophrenia, Dec, 542

Restless Arms syndrome
Olanzapine-induced "Restless Arms Syndrome" (letter), Feb, 89

Rhabdomyolysis
Rhabdomyolysis following dose increase of clozapine and combination therapy with lithium (letter), Aug, 398

© 2009 Lippincott Williams & Wilkins

Risperidone
D2 Receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia (brief report), Dec, 571
Effects of *CYP2D6* and *CYP3A5* genotypes on the plasma concentrations of risperidone and 9-Hydroxyrisperidone in Korean schizophrenic patients (brief report), June, 272
The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder (letter), Aug, 396
Impact of *CYP2D6* genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone, Dec, 537
Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: A case report (letter), Aug, 391

S

Saliva level increase
Dialysis-associated increase in the saliva level of paroxetine (letter), Dec, 619

Schizoaffective disorder
Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type: Response to Khazaal and Zullino (letter), April, 193
Valproic acid-induced myopathy in a patient with schizoaffective disorder (letter), Aug, 402

Schizophrenia
A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive (brief report), June, 267
Acute and chronic effects of ketamine on semantic priming: Modeling schizophrenia? April, 124
Amisulpride treatment for clozapine-induced sialorrhea, April, 189
An open study of aripiprazole and escitalopram for psychotic major depressive disorder (brief report), Feb, 73
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients (brief report), April, 165
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: An open-label cross-taper study, June, 206
Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls, April, 117
Comments on "Optimizing Early Prediction for Antipsychotic Response in Schizophrenia" by Chang et al (letter), June, 311
Comments on "Short-term testosterone augmentation in male schizophrenics: A randomized, double-blind, placebo-controlled trial" by Dr Kho and colleagues, April, 194
Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine (letter), April, 182
Do antipsychotics cost lives or save lives? Risks versus benefits from large epidemiological studies (guest editorial), Dec, 517
D2 Receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia (brief report), Dec, 571
Effects of *CYP2D6* and *CYP3A5* genotypes on the plasma concentrations of risperidone and 9-Hydroxyrisperidone in Korean schizophrenic patients (brief report), June, 272
Ghrelin and leptin levels in patients with schizophrenia treated with antipsychotic monotherapy (letter), June, 304
Glucocorticosteroids associated with a decreased risk of psychosis (brief report), June, 288
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study, Feb, 16
Increase in plasma levels of clozapine after addition of isoniazid, April, 190
Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: A mediation analysis (letter), Oct, 496
Late-onset clozapine-induced hypothermia accompanied by electrocardiogram Osborn waves, April, 183
Management of clozapine-related hepatotoxicity (letter), Dec, 606
Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients, Feb, 26
Mortality rates among patients with schizophrenia and tardive dyskinesia, Feb, 5
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder, Dec, 520
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: An analysis of correlations with efficacy, weight gain, and prolactin concentration (brief report), June, 278
Onset and persistence of antipsychotic response in patients with schizophrenia, Dec, 542
Oral urea treatment for polydipsia-hyponatremia syndrome in patients with schizophrenia (letter), Oct, 499
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21
Predictors of abstinence and changes in psychiatric symptoms in a pooled sample of smokers with schizophrenia receiving combination pharmacotherapy and behavioral therapy for smoking cessation (letter), Dec, 601
Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: A 1-year naturalistic follow-up study (letter), Aug, 394
Reply to comments on "Optimizing early prediction for antipsychotic response in schizophrenia" (letter), Aug, 391
Reply to the comments by Dr Pae and Drs Howes and Hundal for "Short-term testosterone augmentation in male schizophrenics: A randomized, double-blind placebo-controlled trial" (letter), April, 196
Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia (letter), Aug, 409
Sex hormone augmentation as an adjunctive treatment in schizophrenia (letter), April, 195
Successful switch from clozapine to aripiprazole: A case report, Feb, 93
Synthetic D-9-Tetrahydrocannabinol (Dronabinol) can improve the symptoms of schizophrenia, June, 255
Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs, April, 141
Two patients with recurring syndrome of inappropriate secretion of antidiuretic hormone on multiple atypical antipsychotics, April, 187

Schizotypal personality disorder
The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder (letter), Aug, 396

Screening test
Evaluation of a urine on-site drugs of abuse screening test in patients admitted to a psychiatric emergency unit, June, 248

Second-generation antipsychotics (SGAs)
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics, Dec, 529

Sedation
Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers, Oct, 426

Selective serotonin reuptake inhibitors (SSRIs)
Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms (letter), Aug, 403
Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction, Dec, 555
Bruxism associated with serotonin reuptake inhibitors: Two cases (letter), Dec, 620
Dialysis-associated increase in the saliva level of paroxetine (letter), Dec, 619
Sexual dysfunction, depression, and the impact of antidepressants, April, 157
Successful aripiprazole augmentation in a child with drug-resistant obsessive-compulsive disorder (letter), Dec, 607
Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis (review article), June, 259

Semantic priming
Acute and chronic effects of ketamine on semantic priming: Modeling schizophrenia? April, 124

© 2009 Lippincott Williams & Wilkins

Serotonin
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65

Sertraline
Antidepressant drug prescription and risk of abnormal bleeding: A case-control study, Feb, 33
Putative neuroleptic malignant syndrome associated with sertraline withdrawal (letter), June, 300
Sertraline-induced photoallergic reaction, Feb, 95
Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis (review article), June, 259

Serum lipid profiles
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics, Dec, 529

Severe mental disorders
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109

Sex hormone-binding globulin (SHBG)
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions, April, 109

Sexual dysfunction
Sexual dysfunction, depression, and the impact of antidepressants, April, 157
Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis (review article), June, 259

Sialorrhea
Amisulpride treatment for clozapine-induced sialorrhea (letter), April, 189

Smell identification test
Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil (brief report), Aug, 387

Smoking
Aripiprazole augmentation for a patient with partial remission of panic disorder (letter), June, 301
Cerebral monoamine oxidase a inhibition in tobacco smokers confirmed with PET and [^{11}C]Befloxatone (brief report), Feb, 86
Methadone-Nicotine interactions in methadone maintenance treatment patients, June, 231
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: An analysis of correlations with efficacy, weight gain, and prolactin concentration (brief report), June, 278
Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians (guest editorial), June, 201
Predictors of abstinence and changes in psychiatric symptoms in a pooled sample of smokers with schizophrenia receiving combination pharmacotherapy and behavioral therapy for smoking cessation (letter), Dec, 601

Social anxiety
A randomized controlled trial of atomoxetine in generalized social anxiety disorder, Dec, 561
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: An open-label cross-taper study, June, 206

Social phobia
A randomized controlled trial of atomoxetine in generalized social anxiety disorder, Dec, 561

Source unreliability
Sources of unreliability in depression ratings (brief report), Feb, 82

Standardized Stepwise Drug Treatment Regimen (SSTR)
Efficacy of an algorithm-guided treatment compared with treatment as usual: A randomized, controlled study of inpatients with depression, Aug, 327

Steady-state serum concentrations
Impact of *CYP2D6* genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone, Dec, 537

Stimulant effects
Comparing the stimulant effects of the H1-antagonist fexofenadine with 2 psychostimulants, modafinil and methylphenidate, Oct, 439

Stimulants
Atomoxetine and cerebrovascular outcomes in adults, Oct, 453
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study, June, 239

Subjective experience
Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state, Oct, 421

Substance abuse
Evaluation of a urine on-site drugs of abuse screening test in patients admitted to a psychiatric emergency unit, June, 248

Synthetic D-9-Tetrahydrocannabinol (Dronabinol)
Synthetic D-9-Tetrahydrocannabinol (Dronabinol) can improve the symptoms of schizophrenia, June, 255

T

Tardive dyskinesia
An open study of aripiprazole and escitalopram for psychotic major depressive disorder (brief report), Feb, 73
Effect of donepezil on tardive dyskinesia, Feb, 102
Mortality rates among patients with schizophrenia and tardive dyskinesia, Feb, 5

Tardive dystonia
Remission of tardive dystonia with electroconvulsive therapy (letter), June, 314

Targeted medication
Targeted naltrexone for problem drinkers, Aug, 350

Temazepam
Highway driving in the elderly the morning after bedtime use of hypnotics: A comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo, Oct, 432

Testosterone replacement
Effects of testosterone replacement in middle-aged men with dysthymia: A randomized, placebo-controlled clinical trial, June, 216

Tiagabine
Questionable tolerability of tiagabine in generalized anxiety disorder (letter), June, 314

Topiramate
Effects of topiramate on smoking in patients with schizo affective disorder, bipolar type: Response to Khazaal and Zullino (letter), April, 193
Modulation of impulsivity by topiramate implications for the treatment of alcohol dependence (brief report), Dec, 584
Topiramate for smoking cessation and the importance to distinguish withdrawal-motivated consumption and cue-triggered automatism, April, 192

Tourette disorder
Vocal tics associated with ziprasidone (letter), Dec, 611

Traumatic brain injury
Impact of early immediate pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: A meta-analysis (review), Oct, 468

Trazodone
Psychotropic drugs associated with corrected QT interval prolongation, Feb, 9
Trazodone hypnotic effect and nocturnal melatonin secretion, Feb, 97

Treatment
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: Relationship to alcohol withdrawal symptoms, Aug, 334

Treatment as usual
Efficacy of an algorithm-guided treatment compared with treatment as usual: A randomized, controlled study of inpatients with depression, Aug, 327

Treatment discontinuation
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder, Dec, 520

Treatment outcomes
Reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit/hyperactivity disorder the role of comorbidities (letter), Dec, 614

Treatment predictors
Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response, Aug, 343

© 2009 Lippincott Williams & Wilkins

Treatment resistance
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial, Feb, 51

Treatment response
Onset and persistence of antipsychotic response in patients with schizophrenia, Dec, 542
Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil (brief report), Aug, 387

Triazolam
Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers, Oct, 426

Trismus
Trismus Induced by fluoxetine (letter), June, 306

U

Unipolar psychotic depression
Treatment of unipolar psychotic depression: An open study of lithium addition in refractory psychotic depression (letter), Oct, 513

V

Valproate
A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive (brief report), June, 267
Eosinophilic pleural effusion associated with the addition of sodium valproate (letter), June, 310
Remission of tardive dystonia with electroconvulsive therapy (letter), June, 314

Valproic acid
Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: A case report (letter), Oct, 509

Venlafaxine
Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers, Feb, 39
Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services, Dec, 565
Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status (brief report), Aug, 383

Vitamin E
Combination therapy of acetylcholinesterase inhibitor and Vitamin E in Alzheimer disease (letter), Oct, 511

Vocal tics
Vocal tics associated with ziprasidone (letter), Dec, 611

W

Weight gain
A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive (brief report), June, 267
ABCB1 and cytochrome p450 polymorphisms: Clinical pharmacogenetics of clozapine, Aug, 319
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: An open-label cross-taper study, June, 206
Association between *HTR2C* and *HTR2A* polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine (brief report), Feb, 65
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: A pooled analysis of 2 studies (brief report), Aug, 362
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: An analysis of correlations with efficacy, weight gain, and prolactin concentration (brief report), June, 278
Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication, Feb, 21

Women
Randomized, double-blind, placebo-controlled trial of *Cimicifuga racemosa* (Black cohosh) in women with anxiety disorder due to menopause (brief report), Oct, 478

Z

Ziprasidone
Vocal tics associated with ziprasidone (letter), Dec, 611

Zolpidem
Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder, June, 222

Zopiclone
Highway driving in the elderly the morning after bedtime use of hypnotics: A comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo, Oct, 432

© 2009 Lippincott Williams & Wilkins